Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席医疗官Dan Karlin最近出售了公司6,643股普通股。该公司是一家市值5.02亿美元的生物科技公司，其股票在过去一年中上涨超过100%。根据 InvestingPro 的数据，分析师对MNMD保持看好态度，多项关键指标显示公司财务状况良好。这次出售是在2024年12月26日执行的，属于根据规则10b5- ...

Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席法务官Mark ...

Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 10.8% during ...

MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized ...

NEW YORK, December 19, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a ...

(NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results ...

(NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient ...

NEW YORK, December 19, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company ...

Detailed price information for Mind Medicine Mindmed Inc (MNMD-Q) from The Globe and Mail including charting and trades.